- Gilead Sciences Inc.’s remdesivir is ineffective in treating hospitalized Covid-19 patients.
- It was among the drugs President Donald Trump received when he was diagnosed with the disease in early October.
In The BMJ medical journal a panel of WHO-convened experts developing Covid-19 treatment guidelines said“There is currently no evidence that it improves survival or the need for ventilation”, says an article published in Bloomberg.
Negative Impacts on Gilead Sciences Inc.’sGilead shares fell...